- Home
- KZR vs ANTX Comparison
KZR vs ANTX Comparison
Compare KZR & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZR
- ANTX
- Stock Information
- Founded
- KZR 2015
- ANTX 2017
- Country
- KZR United States
- ANTX United States
- Employees
- KZR N/A
- ANTX N/A
- Industry
- KZR Biotechnology: Pharmaceutical Preparations
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- KZR Health Care
- ANTX Health Care
- Exchange
- KZR Nasdaq
- ANTX Nasdaq
- Market Cap
- KZR 29.7M
- ANTX 34.2M
- IPO Year
- KZR 2018
- ANTX 2022
- Fundamental
- Price
- KZR $3.88
- ANTX $1.29
- Analyst Decision
- KZR Hold
- ANTX Buy
- Analyst Count
- KZR 2
- ANTX 2
- Target Price
- KZR $9.00
- ANTX $2.00
- AVG Volume (30 Days)
- KZR 36.2K
- ANTX 81.8K
- Earning Date
- KZR 11-11-2025
- ANTX 11-12-2025
- Dividend Yield
- KZR N/A
- ANTX N/A
- EPS Growth
- KZR N/A
- ANTX N/A
- EPS
- KZR N/A
- ANTX N/A
- Revenue
- KZR N/A
- ANTX N/A
- Revenue This Year
- KZR N/A
- ANTX N/A
- Revenue Next Year
- KZR N/A
- ANTX N/A
- P/E Ratio
- KZR N/A
- ANTX N/A
- Revenue Growth
- KZR N/A
- ANTX N/A
- 52 Week Low
- KZR $3.56
- ANTX $0.98
- 52 Week High
- KZR $9.18
- ANTX $1.68
- Technical
- Relative Strength Index (RSI)
- KZR 49.42
- ANTX 60.03
- Support Level
- KZR $3.79
- ANTX $1.25
- Resistance Level
- KZR $4.10
- ANTX $1.37
- Average True Range (ATR)
- KZR 0.22
- ANTX 0.08
- MACD
- KZR 0.02
- ANTX -0.00
- Stochastic Oscillator
- KZR 61.44
- ANTX 39.57
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.